Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$193.5MBeat by $9.0M
EPS$1.76Beat by $0.24
Revenue estimate$184.5M
EPS estimate$1.52

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$199.6M
EPS estimate$1.68

Financials

Q1 2026

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$1.15B+14.3%
Enterprise value$867.73M-3.2%
P/E15.4×-12.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Segments

By product

See full
Belbuca$52.6M+1.9%
Xtampza ER$50.8M—
Jornay PM$38.9M+36.3%
Nucynta IR$26.1M-4.9%
Nucynta ER$18.2M-7.4%

By segment

See full
Segment$193.5M+8.9%

Versus estimates

Revenue

Q1 2026$193.5MBeat by $9.0M
Q4 2025$205.4MMiss by $913.4KQ3 2025$209.4MBeat by $3.2MQ2 2025$188.0MMiss by $3.3MQ1 2025$177.8MBeat by $4.7MQ4 2024$181.9MBeat by $2.3M

Diluted EPS

Q1 2026$1.76Beat by $0.24
Q4 2025$2.04Miss by $0.10Q3 2025$2.25Beat by $0.39Q2 2025$1.68Beat by $0.06Q1 2025$1.49Beat by $0.06Q4 2024$1.77Beat by $0.23

Ask the moment Collegium Pharmaceutical, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Collegium Pharmaceutical, Inc. report Q1 2026 earnings?
Collegium Pharmaceutical, Inc. (COLL) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Collegium Pharmaceutical, Inc.'s Q1 2026 revenue and EPS?
Collegium Pharmaceutical, Inc. reported revenue of $193.5M and eps of $1.76 for Q1 2026.
Did Collegium Pharmaceutical, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $184.5M by $9.0M. EPS beat the consensus estimate of $1.52 by $0.24.
How did Collegium Pharmaceutical, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.9% from $177.8M a year earlier and eps grew 18.1% from $1.49.
Where can I find Collegium Pharmaceutical, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-031694) and the 10-Q periodic report (0001628280-26-031697) directly on SEC EDGAR. The filing index links above go to sec.gov.